A comparative study of the efficacy of AphthealTM in the management of recurrent minor aphthous ulceration

• Published in: Journal of oral pathology & medicine Vol. 34; no. 7; pp. 413 - 419
• Main Authors: Murray, Brenda, McGuinness, Niall, Biagioni, Paul, Hyland, Paula, Lamey, Philip-John
• Format: Journal Article
• Language: English
• Published: Oxford, UK Munksgaard International Publishers 01.08.2005
• Subjects: amlexanox; aphthous ulceration; prodrome; treatment
• ISSN: 0904-2512; 1600-0714
• DOI: 10.1111/j.1600-0714.2005.00334.x

Background:  Recurrent minor aphthous ulceration (RAU) is a common condition which is multifactorial in origin. Methods:  This study, firstly, aimed to treat the prodromal stage of RAU with AphthealTM (5% amlexanox paste) to determine if ulcer development could be prevented. A second arm of the study investigated treatment of RAU with AphthealTM once ulceration had developed. Ulcer duration, ulcer size and associated pain were measured. Both groups of subjects had previously undergone a no‐treatment run‐in period to establish these parameters over an untreated episode of ulceration. Results:  By day 3, only 35% of the prodromal group had developed an ulcer compared with 97% of the ulcer group (P < 0.001). In the treated ulcer group only 66% had an ulcer present by day 3. Treatment at the onset of prodromal symptoms reduced the maximum ulcer size score by 84% (P < 0.01), extent of ulceration by 88% (P < 0.01), maximum pain score by 69% (P < 0.01) and extent of pain by 85% (P < 0.01) compared to no treatment. Conclusion:  Treatment with AphthealTM at the onset of prodromal RAU symptoms can prevent progression to ulcer development and significantly reduced symptoms if ulcers do develop.